PEL

Piramal Healthcare Limited has informed the Exchange regarding the standalone Results for the quarter ended on 31-DEC-2008 as follows: Net Sales of Rs. 58046 lacs for quarter ending on 31-DEC-2008. Net Profit / (Loss) of Rs. 3867 lacs for the quarter ending on 31-DEC-2008.

Piramal Healthcare Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 31-DEC-2008 as follows: Net Sales of Rs. 82833 lacs for quarter ending on 31-DEC-2008 against Rs. 73233 lacs for the quarter ending on 31-DEC-2007. Net Profit / (Loss) of Rs. 5987 lacs for the quarter ending on 31-DEC-2008 against Rs. 7264 lacs for the quarter ending on 31-DEC-2007.

Piramal Healthcare Limited has informed the Exchange regarding a press release dated December 23, 2008, titled "Piramal Healthcare Limited to acquire Minrad International, Inc.". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Piramal_PR_23122008.zip target=NEW> For more details click here.</a>

Piramal Healthcare Limited has informed the Exchange regarding the press release dated October 22, 2008, titled "Piramal Healthcare reports Q2 FY2009 results; Consolidated Revenues for the quarter up by 17% to Rs.8.9 billion, Operating Profit (excluding FOREX impact) up by 41% to Rs.1.8 billion, Net Profit (before FOREX impact and exceptional items) up by 40% to Rs.1.2 billion�. A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corpo

Piramal Healthcare Limited has informed the Exchange regarding the consolidated Results for the half year ended on 30-SEP-2008 as follows: Net Sales of Rs. 158856 lacs for half year ending on 30-SEP-2008 against Rs. 137264 lacs for the half year ending on 30-SEP-2007. Net Profit / (Loss) of Rs. 14148 lacs for the half year ending on 30-SEP-2008 against Rs. 12821 lacs for the half year ending on 30-SEP-2007.

Piramal Healthcare Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-SEP-2008 as follows: Net Sales of Rs. 63197 lacs for quarter ending on 30-SEP-2008. Net Profit / (Loss) of Rs. 6944 lacs for the quarter ending on 30-SEP-2008.

Piramal Healthcare Limited has informed the Exchange regarding the standalone Results for the half year ended on 30-SEP-2008 as follows: Net Sales of Rs. 111729 lacs for half year ending on 30-SEP-2008. Net Profit / (Loss) of Rs. 12038 lacs for the half year ending on 30-SEP-2008.

Piramal Healthcare Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 30-SEP-2008 as follows: Net Sales of Rs. 88425 lacs for quarter ending on 30-SEP-2008 against Rs. 76457 lacs for the quarter ending on 30-SEP-2007. Net Profit / (Loss) of Rs. 7339 lacs for the quarter ending on 30-SEP-2008 against Rs. 8481 lacs for the quarter ending on 30-SEP-2007.

Piramal Healthcare Limited has informed the Exchange that "Mr. N. Santhanam - Executive Director and Chief Financial Officer, has been appointed as Chief Operating Officer on the Board of the Company. Consequent to the above, Mr. Rajesh Laddha - President (Finance) now holds independent charge of the Finance function of the Company".

Piramal Healthcare Limited has informed the Exchange regarding a press release dated July 24, 2008, titled "Piramal Healthcare reports Q1 FY2009 results; Consolidated Revenues up for the Quarter by 17% to Rs. 7.1 billion, Operating Profit up by 42% to Rs. 1.2 billion, Net Profit up by 57% to Rs. 681 million". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Piramal_PR_24072008.zip target=NEW> For more details click here.</a>

Piramal Healthcare Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-JUN-2008 as follows: Net Sales of Rs. 48912 lacs for quarter ending on 30-JUN-2008 against Rs. 39502 lacs for the quarter ending on 30-JUN-2007. Net Profit / (Loss) of Rs. 5094 lacs for the quarter ending on 30-JUN-2008 against Rs. 3439 lacs for the quarter ending on 30-JUN-2007.

Piramal Healthcare Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 30-JUN-2008 as follows: Net Sales of Rs. 70832 lacs for quarter ending on 30-JUN-2008 against Rs. 60807 lacs for the quarter ending on 30-JUN-2007. Net Profit / (Loss) of Rs. 6809 lacs for the quarter ending on 30-JUN-2008 against Rs. 4340 lacs for the quarter ending on 30-JUN-2007.

Piramal Healthcare Limited has informed the Exchange regarding a press release dated July 22, 2008, titled "Piramal Healthcare launches French dermo-cosmetic range from Pierre Fabre; Ducray range to re-define care for Indian skin". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Piramal_Pr_22072008.zip target=NEW> For more details click here.</a>

Piramal Healthcare Limited has submitted to the Exchange outcome of Annual General Meeting of the Company held on June 26, 2008. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/piramalhealth_OUTAGM_03072008.zip target=NEW> For more details click here.</a>

Piramal Healthcare Limited has informed the Exchange regarding a press release dated July 02, 2008, titled "Piramal Healthcare Acquires Haemaccel Brands Group of PlasmaSelect AG, Germany". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/piramalhealth_PR_02072008.zip target=NEW> For more details click here.</a>

Members of the Exchange are hereby informed that the name of Nicholas Piramal India Ltd. shall be changed to Piramal Healthcare Limited and the trading symbol of the Company be changed from NICOLASPIR to PIRHEALTH w.e.f. June 19, 2008.

Nicholas Piramal India Ltd. has informed the Exchange that the name of Nicholas Piramal India Limited has been changed to 'Piramal Healthcare Limited' with effect from May 13, 2008. A fresh certificate of Incorporation has been issued by the Registrar of Companies, Maharashtra, Mumbai dated May 13, 2008.

Nicholas Piramal India Ltd. has informed the Exchange regarding a press release dated May 13, 2008, titled "Piramal Life Sciences initiates Phase I trials with a new molecule for Type II Diabetes in Europe". Further the Company has informed the Exchange that "It may be recalled that the Company (i.e. Nicholas Piramal) has demerged its NCE Research Unit to Piramal Life Sciences Limited (PLSL) pursuant to the Composite Scheme of Arrangement which has been sanctioned by the Hon'ble Bombay High Court. PLSL has already allotted its shares to the shareholders of the Company under the Scheme. The sha

Nicholas Piramal India Ltd. had informed the Exchange regarding Notice, Explanatory Statement and Postal Ballot Form sent to the shareholders, seeking their assent to the following proposal by way of Special Resolutions: 1) Change of name of the Company to Piramal Healthcare Limited; 2) Increase in the investment limit for FIIs upto 49% of the capital of the Company. The Company has now informed the Exchange that Results of the Postal Ballot were declared on May 07, 2008 both the above proposals have been passed by Special Resolutions with overwhelming requisite majority. Further, the Company

Nicholas Piramal India Ltd. has informed the Exchange regarding a press release dated April 30, 2008, titled "Nicholas Piramal signs Product Development & Licensing Agreement with DxTech for point-of-care diagnostic testing system". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Nicholas_PR_30042008.zip target=NEW> For more details click here.</a>

Nicholas Piramal India Ltd. has informed the Exchange regarding a press release dated April 24, 2008, titled "Nicholas Piramal reports Q4 & FY2008 results; Consolidated Revenues up for the Quarter by 19% to Rs. 7.7 billion, Operating Profit up by 140% to Rs. 2.0 billion, Net Profit up by 142% to Rs. 1.3 billion; Revenues for FY2008 up by 16% to Rs. 28.7 billion, Operating Profit for the year crosses Rs. 5 billion, Net Profit up by 53% to Rs. 3.3 billion making FY2008 a landmark year for the Company". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) un

Nicholas Piramal India Ltd. has informed the Exchange that the Board of Directors at their meeting held on April 24, 2008 has recommended dividend @ 210% (i.e. Rs. 4.20 per equity shares of face value of Rs. 2/- each) for the Financial Year ended March 31, 2008. Further the Company has informed the Exchange that the Register of Members and Share Transfer Books shall remain closed from June 18, 2008 to June 26, 2008 (both days inclusive) for the purpose of declaration of dividend. Board has also fixed the date for the Annual General Meeting (AGM) of the Company on June 26, 2008.

Nicholas Piramal India Ltd. has informed the Exchange regarding the consolidated Results for the quarter ended on 31-MAR-2008 as follows: Net Sales of Rs. 76787 lacs for quarter ending on 31-MAR-2008 against Rs. 64521 lacs for the quarter ending on 31-MAR-2007. Net Profit / (Loss) of Rs. 13282 lacs for the quarter ending on 31-MAR-2008 against Rs. 5495 lacs for the quarter ending on 31-MAR-2007.

Nicholas Piramal India Ltd. has informed the Exchange regarding the standalone Results for the quarter ended on 31-MAR-2008 as follows: Net Sales of Rs. 51697 lacs for quarter ending on 31-MAR-2008 against Rs. 38656 lacs for the quarter ending on 31-MAR-2007. Net Profit / (Loss) of Rs. 11230 lacs for the quarter ending on 31-MAR-2008 against Rs. 2692 lacs for the quarter ending on 31-MAR-2007.

Nicholas Piramal India Ltd. has informed the Exchange regarding the standalone Results for the year ended on 31-MAR-2008 as follows: Net Sales of Rs. 193002 lacs for year ending on 31-MAR-2008 against Rs. 163790 lacs for the year ending on 31-MAR-2007. Net Profit / (Loss) of Rs. 30148 lacs for the year ending on 31-MAR-2008 against Rs. 18828 lacs for the year ending on 31-MAR-2007.

Nicholas Piramal India Ltd. has informed the Exchange regarding the consolidated Results for the year ended on 31-MAR-2008 as follows: Net Sales of Rs. 287284 lacs for year ending on 31-MAR-2008 against Rs. 247193 lacs for the year ending on 31-MAR-2007. Net Profit / (Loss) of Rs. 33378 lacs for the year ending on 31-MAR-2008 against Rs. 21805 lacs for the year ending on 31-MAR-2007.

Nicholas Piramal India Ltd. has informed the Exchange that pursuant to Section 192A of the Companies Act, 1956 ("the Act") read with the Companies (Passing of the Resolution by Postal Ballot) Rules 2001, the following resolutions are proposed to be passed as Special Resolutions, by way of Postal Ballot. 1) Special Resolution for change of name of the Company to Piramal Healthcare Limited; 2) Special Resolution for increase in the investment limit for FIIs upto 49% of the capital of the Company. Mr. N.L. Bhatia, Practising Company Secretary, has been appointed as Scrutinizer for conducting the

Nicholas Piramal India Ltd. has informed the Exchange regarding a press release dated April 15, 2008, titled "Nicholas Piramal India Limited acquires Anafortan and CEFI Brand Groups from Khandelwal Laboratories Pvt. Ltd.". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Nicholas_PR_15042008.zip target=NEW> For more details click here.</a>

Nicholas Piramal India Ltd. has informed the Exchange regarding a press release dated March 11, 2008, titled "Piramal Group announces launch of new corporate identity". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/NICHOLAS_PR_11032008.zip target=NEW> For more details click here.</a>

Nicholas Piramal India Ltd. has informed the Exchange vide its letter dated March 03, 2008 that: "The Board of Directors of the Company has today approved the proposal for change of name of the Company from Nicholas Piramal India Limited to Piramal Healthcare Limited. The proposed change of name is subject to approval of the sharholders and of the central Government under section 21 of the Companies Act, 1956".

Nicholas Piramal India Ltd. has informed the Exchange vide its letter dated February 26, 2008 that "NPIL Research and Development Limited ("NRDL") (name now changed to Piramal Life Sciences Limited) has commenced Phase I studies of a new experimental drug molecule, P1201-07, in The Netherlands." The Company has further informed the Exchange that: "It may be recalled that the Company (i.e. Nicholas Piramal) has demerged its NCE Research Unit to NRDL pursuant to the Composite Scheme of Arrangement which has been sanctioned by the Hon'ble Bombay High Court. The Record Date for issue of shares by

Nicholas Piramal India Ltd. has informed the Exchange vide its letter dated February 22, 2008, that: "NPIL Research & Development Limited ('NRDL') has signed an Agreement with the Department of Biotechnology, New Delhi on 'Screening for Bio-molecules from Microbial Diversity Collected from Different Ecological Niches', thereby initiating an industry - university / national institute partnership programme in drug discovery". The Company has further informed the Exchange that: "It may be recalled that the Company (i.e. Nicholas Piramal) has demerged its NCE Research Unit to NRDL pursuant to the

Nicholas Piramal India Ltd. has informed the Exchange that the Hon'ble High court of Judicature at Bombay has vide its Order dated January 25, 2008 sanctioned the scheme Amalgamation of NPIL Healthcare Private Limited (NHPL) and Nicholas Piramal Consumer Products Private Limited (NPCPL) (the Transferor Companies) with the Company. Certified Copies of the Orders, which were received by NHPL and NPCPL from the Bombay High Court have been filed with the Registrar of Companies (ROC), Maharashtra Mumbai on February 19, 2008. Accordingly, the Scheme has now become effective. Since the Transferor Com

Nicholas Piramal India Ltd. has informed the Exchange that NPIL Research & Development Limited ('NRDL'), has signed a second new drug development agreement with Eli Lilly and Company ('Eli Lilly') to develop and in certain regions, commercialise, a select group of Eli Lilly's pre- clinical drug candidates that span multiple therapeutic areas. Further the Company has informed the Exchange that "It may be recalled that the Company (i.e. Nicholas Piramal) has demerged its NCE Research Unit to NRDL pursuant to the Composite Scheme of Arrangement which has been sanctioned by the Hon'ble Bombay High

Nicholas Piramal India Ltd. has informed the Exchange regarding a press release dated January 25, 2008, titled "Nicholas Piramal and Pierre Fabre Laboratories sign agreement on research in oncology in the presence of French President Nicolas Sarkozy". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Nicholas_PR_25012008.zip target=NEW> For more details click here.</a>

Nicholas Piramal India Ltd. has informed the Exchange that the Hon'ble High Court of Judicature at Bombay has vide its Order dated January 11, 2008 sanctioned the Composite Scheme of Arrangement ("the Scheme") between Nicholas Piramal India Limited ("NPIL") and NPIL Research & Development Limited ("NRDL") for demerger of the NCE Research Unit of NPIL to NRDL. Certified Copy of the Orders which were received by the Company and NRDL from the Bombay High Court have been filed with the Registrar of Companies (ROC), Maharashtra, Mumbai on January 21, 2008. Accordingly, the Scheme has now become eff

Nicholas Piramal India Ltd. has informed the Exchange regarding a press release dated January 22, 2008, titled "Nicholas Piramal India Limited buys Pharmaceuticals business of Healthline Private Limited, Bangalore". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Nicholas_PR_22012008.zip target=NEW> For more details click here.</a>

Nicholas Piramal India Ltd. has submitted to the Exchange the auditor's report in respect of the audited financial results for the quarter ended December 31, 2007. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/NPIL_AuditorsReport_180122008.zip target=NEW> For more details click here.</a>

Nicholas Piramal India Ltd. has informed the Exchange regarding a press release dated January 18, 2008, titled "Nicholas Piramal reports Q3 FY2008 results; Total Revenues grow 13% to Rs. 7.3 billion, Net Profit up by 31% to Rs. 727.6 million; Domestic formulations Sales grow by 15.6% to Rs. 3.4 billion". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/NicholasPir_PR_18012008.zip target=NEW> For more details click here.</a>

Nicholas Piramal India Ltd. has informed the Exchange regarding the consolidated Results for the quarter ended on 31-DEC-2007 as follows: Net Sales of Rs. 73233 lacs for quarter ending on 31-DEC-2007 against Rs. 64949 lacs for the quarter ending on 31-DEC-2006. Net Profit / (Loss) of Rs. 7276 lacs for the quarter ending on 31-DEC-2007 against Rs. 5555 lacs for the quarter ending on 31-DEC-2006.

Nicholas Piramal India Ltd. has informed the Exchange regarding the standalone Results for the quarter ended on 31-DEC-2007 as follows: Net Sales of Rs. 48621 lacs for quarter ending on 31-DEC-2007 against Rs. 40803 lacs for the quarter ending on 31-DEC-2006. Net Profit / (Loss) of Rs. 7382 lacs for the quarter ending on 31-DEC-2007 against Rs. 4330 lacs for the quarter ending on 31-DEC-2006.

Nicholas Piramal India Ltd. has informed the Exchange regarding a press release dated January 15, 2008, titled "Dr L H Hiranandani Hospital outsources its Radiology Department to Nicholas Piramal India Limited Subsidiary Wellspring". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/NicholasPiramal_PR_15012008.zip target=NEW> For more details click here.</a>

Nicholas Piramal India Ltd. has informed the Exchange regarding a press release dated December 19, 2007, titled "Nicholas Piramal enters into a Joint Venture with ARKRAY, Inc. Japan, for marketing Diagnostic products, mainly Self-Monitoring Blood Glucose System in India". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Nicholas_PR_19122007.zip target=NEW> For more details click here.</a>

Members of the Exchange are hereby informed that the trading in the following Preference Shares of Nicholas Piramal India Limited shall be suspended w.e.f. December 28, 2007 on account of redemption as per details given below: 1) 5% Cumulative Redeemable Preference Shares having face value of Rs.100/-, Series - P12) 5% Cumulative Redeemable Preference Shares having face value of Rs.10/-, Series -P2.

Nicholas Piramal India Ltd. has informed the Exchange regarding a press release dated December 10, 2007, titled "Nicholas Piramal secures Product Patent from US Patent & Trademark Office for its Cyclin-Dependent Kinase (CDK) Inhibitors; Dr. Noopur Raje from Dana Faber Cancer Institute presenting on NPIL's lead compound P-276-00 at 49th American Society of Hematology Conference at Atlanta, USA". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=

Nicholas Piramal India Ltd. has informed the Exchange vide its letter dated December 06, 2007, that: "The Board has today decided to redeem the following Preference Shares. The Redemption Date is 9th January 2008: a) 15,00,000 - 5% Cumulative Redeemable Preference Shares of Rs.100 each ("Series I Preference Shares"). b) 2,33,72,280 - 5% Cumulative Redeemable Preference Shares of Rs.10 each ("Series II Preference Shares"). The aforesaid Preference Shares would be redeemed alongwith pro-rata Interim Dividend at the coupon rate (i.e. @5%) from 1st April 2007 upto 9th January 2008, being the date

Nicholas Piramal India Ltd. had informed the Exchange regarding convening of the Meetings of the Equity Shareholders and Series II Preference shareholders on 23rd November, 2007 for approving the Composite Scheme of arrangement between Nicholas Piramal India Limited and NPIL Research & Development Limited by Equity and Series II Preference shareholder of the Company in accordance with the directions of the Hon'ble Bombay High Court. The Meetings were duly convened and held on November 23, 2007 and the Scheme was duly approved by the shareholders. The details of the same shall be available on t

Nicholas Piramal India Ltd. has informed the Exchange regarding the outcome of Extraordinary General Meeting held on November 23, 2007. The summary of the Businesses transacted at the meetings shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/NicholasPir_EGM_29112007.zip target=NEW> For more details click here.</a>

Nicholas Piramal India Ltd. has informed the Exchange regarding a press release dated November 19, 2007, titled "Nicholas Piramal Announces Drug Discovery and Development Agreement with Merck & Co., Inc.". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Nicholas_PR_19112007.zip target=NEW> For more details click here.</a>

Nicholas Piramal India Ltd. has informed the Exchange that: "Mr. Rajesh Khanna, who was a non-executive director on the Board of the Company, has resigned as Director with effect from November 13, 2007. Mr. Khanna was the representative of Express Ventures India Limited, whose shareholding in the Company has substantially reduced".